NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA issued a draft local coverage determination last week proposing that it end coverage of Myriad Genetics' rheumatoid arthritis test Vectra DA.

Explaining its reasoning for ending coverage of Vectra DA, Palmetto cited recent studies that raise questions as to whether the test is effective in assessing disease activity in RA patients. The draft LCD also noted the lack of prospective clinical utility data on the test and the fact that it is not included in the 2015 American College of Rheumatology treatment guidelines.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.